Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. 2008

Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. mbondy@mdanderson.org

Epidemiologists in the Brain Tumor Epidemiology Consortium (BTEC) have prioritized areas for further research. Although many risk factors have been examined over the past several decades, there are few consistent findings, possibly because of small sample sizes in individual studies and differences between studies in patients, tumor types, and methods of classification. Individual studies generally have lacked samples of sufficient size to examine interactions. A major priority based on available evidence and technologies includes expanding research in genetics and molecular epidemiology of brain tumors. BTEC has taken an active role in promoting understudied groups, such as pediatric brain tumors; the etiology of rare glioma subtypes, such as oligodendroglioma; and meningioma, which, although it is not uncommon, has only recently been registered systematically in the United States. There also is a pressing need for more researchers, especially junior investigators, to study brain tumor epidemiology. However, relatively poor funding for brain tumor research has made it difficult to encourage careers in this area. In this report, BTEC epidemiologists reviewed the group's consensus on the current state of scientific findings, and they present a consensus on research priorities to identify which important areas the science should move to address.

UI MeSH Term Description Entries
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D004574 Electromagnetic Fields Fields representing the joint interplay of electric and magnetic forces. Electromagnetic Field,Field, Electromagnetic,Fields, Electromagnetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D020022 Genetic Predisposition to Disease A latent susceptibility to disease at the genetic level, which may be activated under certain conditions. Genetic Predisposition,Genetic Susceptibility,Predisposition, Genetic,Susceptibility, Genetic,Genetic Predispositions,Genetic Susceptibilities,Predispositions, Genetic,Susceptibilities, Genetic
D040421 Cell Phone Analog or digital communications device in which the user has a wireless connection from a telephone to a nearby transmitter. It is termed cellular because the service area is divided into multiple "cells." As the user moves from one cell area to another, the call is transferred to the local transmitter. Car Phone,Cell Phones,Cellular Phone,Mobile Phone,Telephone, Cellular,Mobile Telephone,Portable Cellular Phone,Transportable Cellular Phone,Car Phones,Cellular Phone, Portable,Cellular Phone, Transportable,Cellular Phones,Cellular Phones, Portable,Cellular Phones, Transportable,Cellular Telephone,Cellular Telephones,Mobile Phones,Mobile Telephones,Phone, Car,Phone, Cell,Phone, Cellular,Phone, Mobile,Phones, Car,Phones, Cell,Phones, Cellular,Phones, Mobile,Portable Cellular Phones,Telephone, Mobile,Telephones, Cellular,Telephones, Mobile,Transportable Cellular Phones

Related Publications

Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
December 2014, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
March 2008, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
January 2019, Clinical neuropathology,
Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
January 2017, Clinical neuropathology,
Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
January 2023, Clinical neuropathology,
Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
January 2018, Clinical neuropathology,
Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
January 1992, Journal of neuro-oncology,
Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
January 2021, Clinical neuropathology,
Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
February 1991, Journal of neuro-oncology,
Melissa L Bondy, and Michael E Scheurer, and Beatrice Malmer, and Jill S Barnholtz-Sloan, and Faith G Davis, and Dora Il'yasova, and Carol Kruchko, and Bridget J McCarthy, and Preetha Rajaraman, and Judith A Schwartzbaum, and Siegal Sadetzki, and Brigitte Schlehofer, and Tarik Tihan, and Joseph L Wiemels, and Margaret Wrensch, and Patricia A Buffler, and
January 2015, Clinical neuropathology,
Copied contents to your clipboard!